Related Experiment Video

Updated: Aug 18, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease

Daphne M Geslani1, Mary C Tierney, Nathan Herrmann

  • 1Geriatric Research, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada. daphne.geslani@utoronto.ca

Dementia and Geriatric Cognitive Disorders
|April 2, 2005
PubMed
Abstract

Insights

Mild cognitive impairment (MCI) accurately predicts Alzheimer's disease (AD) conversion within two years in patients referred by primary care physicians. This study established an operational definition for MCI and confirmed its predictive value.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Discrepant findings exist regarding mild cognitive impairment (MCI) accuracy in predicting Alzheimer's disease (AD).
  • Further research is essential to validate MCI's clinical utility and conversion rates before widespread adoption.
  • An operational definition of MCI, aligned with established criteria, is needed.

Purpose of the Study:

  • To operationalize mild cognitive impairment (MCI) criteria consistent with the Mayo Alzheimer's Disease Center.
  • To investigate the conversion rate of MCI to Alzheimer's disease (AD) over a two-year period.
  • To assess the predictive accuracy of MCI for AD development.

Main Methods:

  • An inception cohort of 161 non-demented patients with memory complaints was identified.
  • Patients were classified using MCI criteria at baseline and evaluated annually for AD diagnosis over two years.
  • Logistic regression analysis, controlling for age and education, assessed MCI's predictive accuracy.

Main Results:

  • 35% of patients met MCI criteria at baseline.
  • Conversion rates to AD were 41% after one year and 64% after two years.
  • MCI demonstrated high predictive accuracy: 1-year sensitivity 91%, specificity 79%; 2-year sensitivity 88%, specificity 83%.

Conclusions:

  • Mild cognitive impairment (MCI) serves as an accurate predictor of Alzheimer's disease (AD) within two years.
  • Patient recruitment methods and variations in operationalizing MCI may explain discrepancies in conversion rates across studies.
  • The findings support the use of a standardized MCI definition for predicting AD in clinical settings.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...